39 results on '"Barbieux C"'
Search Results
2. Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity
- Author
-
Darbord, D., primary, Hickman, G., additional, Pironon, N., additional, Barbieux, C., additional, Bonnet‐des‐Claustres, M., additional, Titeux, M., additional, Miskinyte, S., additional, Cordoliani, F., additional, Vignon‐Pennamen, M.D., additional, Amode, R., additional, Hovnanian, A., additional, and Bourrat, E., additional
- Published
- 2021
- Full Text
- View/download PDF
3. 183 Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity
- Author
-
Darbord, D., primary, Hickman, G., additional, Pironon, N., additional, Barbieux, C., additional, Bonnet-des-Claustres, M., additional, Miskinyte, S., additional, Titeux, M., additional, Bourrat, E., additional, and Hovnanian, A., additional
- Published
- 2021
- Full Text
- View/download PDF
4. 228 IL-36 is a hallmark of Netherton syndrome with type I IFN, Th2 and Th9 responses distinguishing its dual clinical presentation
- Author
-
Barbieux, C., primary, Bonnet-des-Claustres, M., additional, Fahrner, M., additional, Tsoi, L., additional, Gouin, O., additional, Petrova, E., additional, Bourrat, E., additional, Schilling, O., additional, Gudjonsson, J., additional, and Hovnanian, A., additional
- Published
- 2021
- Full Text
- View/download PDF
5. 117 Molecular signatures of skin barrier defect and inflammation in Netherton syndrome uncovered by comparing patients to viable Spink5 knock-out mice
- Author
-
Petrova, E., Lopez-Gay Orts, J.M., Fahrner, M., Leturcq, F., Villartay, J.-P.d., Barbieux, C., Tsoi, L., Gudjonsson, J., Schilling, O., and Hovnanian, A.
- Published
- 2023
- Full Text
- View/download PDF
6. The damaged DNA binding 2 protein: a new modulator of TGFβ-1 signaling pathway and membrane nanomechanics in breast cancer cells: P18-002-SH
- Author
-
Barbieux, C., Francius, G., Klotz, R., Besancenot, V., Brunner, E., Soussen, C., Brie, D., Kaminski, S., Becuwe, P., and Grandemange, S.
- Published
- 2015
7. Signatures mutationnelles des carcinomes épidermoïdes cutanés survenant chez les patients atteints d’épidermolyse bulleuse dystrophique récessive
- Author
-
Ragot, H., primary, Titeux, M., additional, Barbieux, C., additional, Gaucher, S., additional, Hanein, S., additional, Battistella, M., additional, Boudan, R., additional, Bourrat, E., additional, and Hovnanian, A., additional
- Published
- 2020
- Full Text
- View/download PDF
8. 884 Treatment of Netherton syndrome patients with Ixekizumab: A case series
- Author
-
Barbieux, C., primary, Bonnet des Claustres, M., additional, Bagot, M., additional, Bourrat, E., additional, and Hovnanian, A., additional
- Published
- 2020
- Full Text
- View/download PDF
9. Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity.
- Author
-
Darbord, D., Hickman, G., Pironon, N., Barbieux, C., Bonnet‐des‐Claustres, M., Titeux, M., Miskinyte, S., Cordoliani, F., Vignon‐Pennamen, M.D., Amode, R., Hovnanian, A., and Bourrat, E.
- Subjects
EPIDERMOLYSIS bullosa ,PHENOTYPES ,ATOPY ,SYMPTOMS ,MAST cells ,IMMUNOGLOBULIN E ,IMMUNITY - Abstract
Background: Dystrophic epidermolysis bullosa pruriginosa (DEB‐Pr) is a rare subtype of hereditary epidermolysis bullosa, with a poorly understood pathogenesis and no satisfactory treatment. Objectives: To assess the clinical and biological features, genetic basis and therapeutic management, to better characterize this rare genodermatosis. Methods: We have conducted a retrospective study, reviewing the clinical presentation, genetic diagnosis, immunohistopathological findings and biological characteristics and management of patients with dystrophic epidermolysis bullosa pruriginosa. This study was conducted in the Department of Dermatology at Saint‐Louis Hospital and the Department of Genetics at Necker Hospital (Paris, France). All patients with a diagnosis of DEB‐Pr seen between 2010 and 2020 were included. Results: Seven patients were included, the average age of 50.1 years [range 36–76]. Pruriginous‐lichenified papules, plaques or nodules appeared at 27.6 years on average [range 7–66] on pretibial areas and forearms, associated with milia and toenails dystrophy. All patients received multiple treatments, but none could sustainably reduce pruritus. Immunohistopathological analysis of lesion skin revealed subepidermal blister with fibrosis, milia and mast cell infiltration. Serum TNFα, IL1β and IL6 levels were elevated in 2/6 patients. Total serum IgE levels were increased in 7/7 patients, with no history of atopy. Immunophenotyping of circulating T‐cells revealed an increased Th2 subset in 4/4 patients, with reduced Th1 and Th17 subpopulations. Genetic analysis of COL7A1 identified 7 distinct causative mutations, six of which were new. Intra‐familial clinical variability was documented in 5/7 patients and was associated with the co‐inheritance of a recessive COL7A1 mutation or an FLG2 mutation in 2 families. Conclusion: Our study confirms the stereotyped presentation of DEB‐Pr with large intra‐familial variability in disease expression. Mast cell infiltration, elevated IgE and increased Th2 subset without atopy strongly support a role of Th2‐mediated immunity in DEB‐Pr, and further argue for new targeted therapeutic options such as dupilumab. Linked Commentary Z. Ruszczak and S. Abdelhadi. J Eur Acad Dermatol Venereol 2022; 36: 13–16. https://doi.org/10.1111/jdv.17821. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. 200 Transgenic kallikrein 14 mice display major hair defects associated with desmoglein 3 and 4 degradation and an inflammatory signature
- Author
-
Gouin, O., primary, Barbieux, C., additional, Leturcq, F., additional, Bonnet des Claustres, M., additional, Petrova, E., additional, and Hovnanian, A., additional
- Published
- 2019
- Full Text
- View/download PDF
11. Un tableau radiologique atypique d’un lymphome cérébral primitif
- Author
-
Lim, L., primary, Tanguy, J.-Y., additional, Della Schiava, L., additional, Ghitu-Barbieux, C., additional, Godard, S., additional, Verny, C., additional, and Morar-Precup, A.-D., additional
- Published
- 2014
- Full Text
- View/download PDF
12. P167 L’architecture des îlots pancréatiques encapsulés est perturbée avant et après greffe
- Author
-
Montanari, E., primary, Parnaud, G., additional, Morel, P., additional, Sinigaglia, C., additional, Lavallard, V., additional, Bedat, B., additional, Meier, R., additional, Barbieux, C., additional, Berney, T., additional, and Bosco, D., additional
- Published
- 2014
- Full Text
- View/download PDF
13. Contractualisation Competition Regulation - Three Guidelines for Improved Efficiency in Urban Public Transport
- Author
-
Barbieux, C.
- Abstract
Institute of Transport and Logistics Studies. Faculty of Economics and Business. The University of Sydney
- Published
- 1999
14. Harcèlement au travail : étude des cas rencontrés en service interentreprises et du devenir de ces salariés un an après la dernière consultation
- Author
-
Baugé, J., primary, Pain, F., additional, Barbieux, C., additional, Biju, C., additional, Buisson, A., additional, Damas, M., additional, Dupont, S., additional, Huguet, C., additional, Le Floch, M.H., additional, Mailliez, G., additional, Potreau, M., additional, Renaud, C., additional, Rosmorduc, B., additional, Roux, J., additional, and Torchut, B., additional
- Published
- 2004
- Full Text
- View/download PDF
15. Prolonged Efficiency of Secondary Prophylaxis with Colistin Aerosols for Respiratory Infection Due to Pseudomonas aeruginosa in Patients Infected with Human Immunodeficiency Virus
- Author
-
Zylberberg, H., primary, Vargaftig, J., additional, Barbieux, C., additional, Pertuiset, N., additional, Rothschild, C., additional, and Viard, J.-P., additional
- Published
- 1996
- Full Text
- View/download PDF
16. Comparative analyses of Netherton syndrome patients and Spink5 conditional knock-out mice uncover disease-relevant pathways.
- Author
-
Petrova E, López-Gay JM, Fahrner M, Leturcq F, de Villartay JP, Barbieux C, Gonschorek P, Tsoi LC, Gudjonsson JE, Schilling O, and Hovnanian A
- Subjects
- Animals, Humans, Mice, Inflammation, Interleukin-17 genetics, Mice, Knockout, Peptide Hydrolases, Netherton Syndrome genetics, Netherton Syndrome metabolism, Netherton Syndrome pathology, Serine Peptidase Inhibitor Kazal-Type 5 genetics
- Abstract
Netherton syndrome (NS) is a rare skin disease caused by loss-of-function mutations in the serine peptidase inhibitor Kazal type 5 (SPINK5) gene. Disease severity and the lack of efficacious treatments call for a better understanding of NS mechanisms. Here we describe a novel and viable, Spink5 conditional knock-out (cKO) mouse model, allowing to study NS progression. By combining transcriptomics and proteomics, we determine a disease molecular profile common to mouse models and NS patients. Spink5 cKO mice and NS patients share skin barrier and inflammation signatures defined by up-regulation and increased activity of proteases, IL-17, IL-36, and IL-20 family cytokine signaling. Systemic inflammation in Spink5 cKO mice correlates with disease severity and is associated with thymic atrophy and enlargement of lymph nodes and spleen. This systemic inflammation phenotype is marked by neutrophils and IL-17/IL-22 signaling, does not involve primary T cell immunodeficiency and is independent of bacterial infection. By comparing skin transcriptomes and proteomes, we uncover several putative substrates of tissue kallikrein-related proteases (KLKs), demonstrating that KLKs can proteolytically regulate IL-36 pro-inflammatory cytokines. Our study thus provides a conserved molecular framework for NS and reveals a KLK/IL-36 signaling axis, adding new insights into the disease mechanisms and therapeutic targets., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study.
- Author
-
Courvoisier N, Storari C, Lesage S, Vittoz L, Barbieux C, Peytremann-Bridevaux I, Gilles I, and Calmy A
- Subjects
- Anti-Retroviral Agents therapeutic use, Female, Health Personnel, Humans, Pregnancy, Qualitative Research, Switzerland, HIV Infections drug therapy
- Abstract
Objectives: Women are underrepresented in most HIV clinical trials in Western countries, but their participation remains crucial as the lack of information on sex- and gender-specific effects may hinder the safety and efficacy of antiretroviral treatments. The aim of this study was to identify barriers to and facilitators of women's participation in HIV clinical trials in Switzerland., Methods: We conducted semi-structured interviews among 20 women with HIV to explore factors associated with non-participation in clinical trials. The interviewer presented to participants a clinical trial's description and discussed it with them. Lexicometric analysis on transcribed interviews identified three themes and eight sub-themes related to the pros and cons of participation in HIV clinical trials., Results: Participants evoked mainly decision-making drivers, concerns for women living with HIV and treatment side-effects. They highlighted the need for extensive information provided by trusted healthcare professionals on the research process as central to the decision to enrol in HIV clinical trials. Familial responsibilities were clearly identified as barriers to their participation, but not pregnancy. Additional preoccupations were other health concerns and comorbidities and the consequences of stopping ongoing antiretroviral treatments., Conclusions: To overcome the barriers to the participation of women living with HIV in clinical research in Western countries, healthcare professionals and researchers should increase women's research literacy by involving them in the study design and by tailoring clinical trials to their social roles and health concerns. Trust in professionals is a facilitator of enrolment of women living with HIV that should be maintained., (© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.)
- Published
- 2022
- Full Text
- View/download PDF
18. Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses.
- Author
-
Barbieux C, Bonnet des Claustres M, Fahrner M, Petrova E, Tsoi LC, Gouin O, Leturcq F, Nicaise-Roland P, Bole C, Béziat V, Bourrat E, Schilling O, Gudjonsson JE, and Hovnanian A
- Subjects
- Epidermis pathology, Humans, Interferon-alpha, Interleukin-17 genetics, Proteinase Inhibitory Proteins, Secretory genetics, Serine Peptidase Inhibitor Kazal-Type 5 genetics, Skin pathology, Hypersensitivity pathology, Netherton Syndrome genetics, Skin Diseases pathology
- Abstract
Background: Netherton syndrome (NS) is a rare recessive skin disorder caused by loss-of-function mutations in SPINK5 encoding the protease inhibitor LEKTI (lymphoepithelial Kazal-type-related inhibitor). NS patients experience severe skin barrier defects, display inflammatory skin lesions, and have superficial scaling with atopic manifestations. They present with typical ichthyosis linearis circumflexa (NS-ILC) or scaly erythroderma (NS-SE)., Objective: We used a combination of several molecular profiling methods to comprehensively characterize the skin, immune cells, and allergic phenotypes of NS-ILC and NS-SE patients., Methods: We studied a cohort of 13 patients comprising 9 NS-ILC and 4 NS-SE., Results: Integrated multiomics revealed abnormal epidermal proliferation and differentiation and IL-17/IL-36 signatures in lesion skin and in blood in both NS endotypes. Although the molecular profiles of NS-ILC and NS-SE lesion skin were very similar, nonlesion skin of each disease subtype displayed distinctive molecular features. Nonlesion and lesion NS-SE epidermis showed activation of the type I IFN signaling pathway, while lesion NS-ILC skin differed from nonlesion NS-ILC skin by increased complement activation and neutrophil infiltration. Serum cytokine profiling and immunophenotyping of circulating lymphocytes showed a T
H 2-driven allergic response in NS-ILC, whereas NS-SE patients displayed mainly a TH 9 axis with increased CCL22/MDC and CCL17/TARC serum levels., Conclusions: This study confirms IL-17/IL-36 as the predominant signaling axes in both NS endotypes and unveils molecular features distinguishing NS-ILC and NS-SE. These results identify new therapeutic targets and could pave the way for precision medicine of NS., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
19. Screening of Work-Related Musculoskeletal Upper Limb Disorders Using the SALTSA Protocol: A Work-Site Study in Belgium.
- Author
-
Van Dyck L, Baecke M, Grosjean M, Isaie H, Gregoire Y, Barbieux C, Tock R, and Verbrugghe M
- Subjects
- Belgium epidemiology, Female, Humans, Male, Prevalence, Risk Factors, Upper Extremity, Workplace, Musculoskeletal Diseases epidemiology, Occupational Diseases epidemiology
- Abstract
Background: Long-term absenteeism continues to rise in Belgium and musculoskeletal disorders (MSDs) have been considered a primary cause. However, there is still uncertainty about the prevalence of MSDs, and about the contribution of work-related factors in the etiology of MSDs. SALTSA, which was developed in 2001, is a European diagnostic criterion document that aims to standardize the reporting of work-related upper limb MSDs (ULMSDs). The purpose of this work-site study was to implement SALTSA in daily occupational health practice and to determine the prevalence of ULMSDs in a Belgian company., Methods: During health examinations, occupational health nurses and an occupational health physician screened employees in a company with ergonomically high-risk activities for the occurrence of ULMSDs using the SALTSA protocol. In order to explore associations between ULMSDs and lifestyle and work-related factors, bivariate and logistic regression analyses were performed., Findings: Three hundred and eight (94.0%, 308/328) employees were screened resulting in an ULMSD prevalence of 20.5% (95% CI = [16.0-25.3]). Rotator cuff syndrome was the most common condition. Prevalence varied significantly between men (9.6%, 95% CI = [5.6-14.9]) and women (35.0%, 95% CI = [26.9-43.9]). Being female ( p < .001) and working in the cabling assembly unit ( p = .002) were found to be significant predictors of ULMSDs., Conclusion/application to Practice: By using the SALTSA protocol in occupational health practices, ULMSDs can be screened unequivocally, enabling comparisons between different occupational sectors and countries. Occupational health nurses can play an important role in detecting and screening MSDs among workers.
- Published
- 2021
- Full Text
- View/download PDF
20. An inhibitor-mediated beta-cell dedifferentiation model reveals distinct roles for FoxO1 in glucagon repression and insulin maturation.
- Author
-
Casteels T, Zhang Y, Frogne T, Sturtzel C, Lardeau CH, Sen I, Liu X, Hong S, Pauler FM, Penz T, Brandstetter M, Barbieux C, Berishvili E, Heuser T, Bock C, Riedel CG, Meyer D, Distel M, Hecksher-Sørensen J, Li J, and Kubicek S
- Subjects
- Adult, Animals, Cell Dedifferentiation, Cells, Cultured, Female, Humans, Male, Mice, Middle Aged, Forkhead Box Protein O1 metabolism, Glucagon metabolism, Insulin metabolism, Insulin-Secreting Cells metabolism
- Abstract
Objective: The loss of forkhead box protein O1 (FoxO1) signaling in response to metabolic stress contributes to the etiology of type II diabetes, causing the dedifferentiation of pancreatic beta cells to a cell type reminiscent of endocrine progenitors. Lack of methods to easily model this process in vitro, however, have hindered progress into the identification of key downstream targets and potential inhibitors. We therefore aimed to establish such an in vitro cellular dedifferentiation model and apply it to identify novel agents involved in the maintenance of beta-cell identity., Methods: The murine beta-cell line, Min6, was used for primary experiments and high-content screening. Screens encompassed a library of small-molecule drugs representing the chemical and target space of all FDA-approved small molecules with an automated immunofluorescence readout. Validation experiments were performed in a murine alpha-cell line as well as in primary murine and human diabetic islets. Developmental effects were studied in zebrafish and C. elegans models, while diabetic db/db mouse models were used to elucidate global glucose metabolism outcomes., Results: We show that short-term pharmacological FoxO1 inhibition can model beta-cell dedifferentiation by downregulating beta-cell-specific transcription factors, resulting in the aberrant expression of progenitor genes and the alpha-cell marker glucagon. From a high-content screen, we identified loperamide as a small molecule that can prevent FoxO inhibitor-induced glucagon expression and further stimulate insulin protein processing and secretion by altering calcium levels, intracellular pH, and FoxO1 localization., Conclusions: Our study provides novel models, molecular targets, and drug candidates for studying and preventing beta-cell dedifferentiation., (Copyright © 2021 The Authors. Published by Elsevier GmbH.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
21. Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial.
- Author
-
Courlet P, Barbieux C, Sculier D, Wandeler G, Stoeckle M, Bernasconi E, Braun D, Vernazza P, Cavassini M, Marinosci A, Smit M, Günthard HF, Schmid P, Limacher A, Guidi M, Alves Saldanha S, Decosterd LA, and Calmy A
- Subjects
- Female, Heterocyclic Compounds, 3-Ring adverse effects, Humans, Oxazines, Piperazines, Pyridones therapeutic use, Treatment Outcome, Anti-HIV Agents adverse effects, HIV Infections drug therapy, HIV Integrase Inhibitors adverse effects
- Abstract
This study aims to evaluate the association between dolutegravir (DTG) pharmacokinetic parameters and weight changes in treatment-experienced people with HIV (PWHIV) from the Simpl'HIV study newly switched to a dual DTG-based regimen. We used multivariable linear regressions to evaluate the association between DTG pharmacokinetic parameters at week 48 (derived using an established model) and weight change between week 0 and week 48. We adjusted our model for potential confounders including CD4 nadir, female sex, African origin, age, weight at week 0 and presence of a non-nucleoside reverse transcriptase inhibitor-based regimen before switch to DTG. The analysis included data from 39 PWHIV. An average significant weight gain of 2.4 kg was observed between baseline and week 48. DTG plasma exposure was not significantly associated with weight gain, even after adjusting for potential confounders (P = .9). We found no significant association between DTG pharmacokinetic parameters and weight gain amongst PWHIV newly switched to a DTG-based dual regimen., (© 2021 British Pharmacological Society.)
- Published
- 2021
- Full Text
- View/download PDF
22. Brief Report: Representations and Willingness of People Living With HIV in Switzerland to Participate in HIV Cure Trials: The Case of Gene-Modified Cell Therapies.
- Author
-
Gilles I, Lesage S, Barbieux C, Alessandrini M, Jackson-Perry D, Vittoz L, Peytremann-Bridevaux I, and Calmy A
- Subjects
- Humans, Qualitative Research, Switzerland, Cell- and Tissue-Based Therapy methods, Genetic Therapy methods, HIV Infections therapy, Therapeutic Human Experimentation
- Abstract
Background: Recent advances made in cell and gene therapies for cancer suggest that they represent plausible strategies to cure HIV. However, the health risks and constraints associated with these therapies require a deeper understanding of the expectations of such treatments among people living with HIV (PLWH)., Methods: We conducted 15 semistructured in-depth interviews among patients from 2 HIV units in Switzerland. After a conversation about their perceptions of research on HIV therapies, participants were provided with a trial description using a gene-modified cell therapy as a potentially curative approach. They were invited to discuss how they might consider participation in the trial. Content analysis was performed to identify core themes., Results: Participants perceived the trial as burdensome and uncertain. Most were aware that cure was not guaranteed, and 6 of the 15 considered that they would participate. Two main concerns were expressed about potential participation: (1) the impact on the professional life and fear to be stigmatized because of this and (2) the fact that stopping antiretroviral treatment would challenge the balance currently achieved in their lives. The decision to participate would depend on their understanding of the trial, the availability of sufficient information, and the relationship with health care professionals., Conclusion: Involving PLWH in early stages of research would be crucial to improve their understanding of gene-modified cell therapies. It could also help adapt trials to address key factors, including the anticipation of stigma, which may discourage PLWH from participating in treatment research., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Duality of Netherton syndrome manifestations and response to ixekizumab.
- Author
-
Barbieux C, Bonnet des Claustres M, de la Brassinne M, Bricteux G, Bagot M, Bourrat E, and Hovnanian A
- Subjects
- Administration, Cutaneous, Adult, Combined Modality Therapy methods, Female, Humans, Induction Chemotherapy methods, Injections, Subcutaneous, Maintenance Chemotherapy methods, Male, Netherton Syndrome drug therapy, Netherton Syndrome immunology, Netherton Syndrome pathology, Severity of Illness Index, Skin drug effects, Skin immunology, Skin pathology, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized administration & dosage, Glucocorticoids administration & dosage, Netherton Syndrome diagnosis
- Published
- 2021
- Full Text
- View/download PDF
24. Secukinumab Therapy for Netherton Syndrome.
- Author
-
Luchsinger I, Knöpfel N, Theiler M, Bonnet des Claustres M, Barbieux C, Schwieger-Briel A, Brunner C, Donghi D, Buettcher M, Meier-Schiesser B, Hovnanian A, and Weibel L
- Subjects
- Adult, Antibodies, Monoclonal, Humanized adverse effects, Chemokine CCL20 blood, Child, Compassionate Use Trials, Dermatologic Agents adverse effects, Female, Humans, Interleukin-17 metabolism, Male, Netherton Syndrome complications, Netherton Syndrome metabolism, Onychomycosis chemically induced, Phenotype, Pruritus etiology, Quality of Life, Severity of Illness Index, Skin metabolism, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Dermatologic Agents therapeutic use, Netherton Syndrome drug therapy
- Abstract
Importance: Netherton syndrome (NS) is a rare, severe genetic disorder of cornification with high morbidity. Treatment for NS has been notoriously difficult. Recent studies showed an upregulated helper T cell (TH) 17/interleukin 23 (IL-23) pathway in NS, suggesting the possibility of treatment strategies that target IL-17., Objective: To evaluate the clinical response of NS to treatment with the IL-17 antagonist secukinumab., Design, Setting, and Participants: This case series study reports the experience of compassionate use therapy with secukinumab in 4 patients with severe NS, including 2 children, from December 1, 2018, to December 1, 2019, with 3 patients still undergoing treatment at the time of final analysis. Data were analyzed from December 1, 2018, to December 1, 2019., Main Outcomes and Measures: Expression of IL-17 in the skin was evaluated by immunohistochemical analysis, and serum cytokine concentrations were measured using a commercially available assay. Treatment response was assessed using the Ichthyosis Area and Severity Index (IASI) total score, including measures of erythema and scaling, the Dermatology Life Quality Index (DLQI), and the 5-D itch scale., Results: In all 4 patients (age range, 9-27 years; 3 male and 1 female), immunostaining with an IL-17A antibody showed an increased number of positive cells in lesional skin. Cytokine assessment in serum samples revealed increased levels of CCL20. Treatment duration with secukinumab was 3 to 12 months at the time of this report. After 3 months of therapy, IASI scores were reduced by 44% to 88%, DLQI scores were reduced by 40% to 76%, and 5-D itch scale scores were reduced by 27% to 62%. This outcome was sustained at the 6-month follow-up. Two patients with an erythrodermic phenotype showed marked improvement of all parameters. A refractory palmoplantar eczematous eruption occurred in 2 patients, and a candidal nail infection developed in 2 patients. No severe adverse events were reported., Conclusions and Relevance: This initial case series reporting the use of anti-IL-17 therapy in NS demonstrated marked cutaneous improvement, particularly in 2 pediatric patients with erythrodermic phenotypes. Further studies are needed to evaluate the long-term benefit of this potential treatment modality.
- Published
- 2020
- Full Text
- View/download PDF
25. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
- Author
-
Gouin O, Barbieux C, Leturcq F, Bonnet des Claustres M, Petrova E, and Hovnanian A
- Subjects
- Animals, Desmoglein 3 genetics, Desmoglein 3 metabolism, Desmogleins genetics, Desmogleins metabolism, Disease Models, Animal, Epidermis immunology, Epidermis metabolism, Female, Hair immunology, Hair metabolism, Humans, Immunity, Innate, Kallikreins genetics, Loss of Function Mutation, Mice, Transgenic, Netherton Syndrome genetics, Netherton Syndrome immunology, Proteolysis, Recombinant Proteins genetics, Recombinant Proteins metabolism, Serine Peptidase Inhibitor Kazal-Type 5 genetics, Epidermis pathology, Hair pathology, Interleukin-1 metabolism, Kallikreins metabolism, Netherton Syndrome pathology
- Abstract
Netherton syndrome is a rare autosomal recessive skin disease caused by loss-of-function mutations in SPINK5 encoding LEKTI protein that results in unopposed activity of epidermal kallikrein-related peptidases (KLKs), mainly KLK5, KLK7, and KLK14. Although the function of KLK5 and KLK7 has been previously studied, the role of KLK14 in skin homeostasis and its contribution to Netherton syndrome pathogenesis remains unknown. We generated a transgenic murine model overexpressing human KLK14 (TghKLK14) in stratum granulosum. TghKLK14 mice revealed increased proteolytic activity in the granular layers and in hair follicles. Their hair did not grow and displayed major defects with hyperplastic hair follicles when hKLK14 was overexpressed. TghKLK14 mice displayed abnormal epidermal hyperproliferation and differentiation. Ultrastructural analysis revealed cell separation in the hair cortex and increased thickness of Huxley's layer. Desmoglein (Dsg) 2 staining was increased, whereas Dsg3 and Dsg4 were markedly reduced. In vitro studies showed that hKLK14 directly cleaves recombinant human DSG3 and recombinant human DSG4, suggesting that their degradation contributes to hair abnormalities. Their skin showed an inflammatory signature, with enhanced expression of IL-36 family members and their downstream targets involved in innate immunity. This in vivo study identifies KLK14 as an important contributor to hair abnormalities and skin inflammation seen in Netherton syndrome., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
26. Effects of Bioactive Marine-Derived Liposomes on Two Human Breast Cancer Cell Lines.
- Author
-
Li J, Elkhoury K, Barbieux C, Linder M, Grandemange S, Tamayol A, Francius G, and Arab-Tehrany E
- Subjects
- Animals, Antineoplastic Agents pharmacology, Docosahexaenoic Acids pharmacology, Eicosapentaenoic Acid pharmacology, Female, Humans, Liposomes pharmacology, MCF-7 Cells drug effects, Antineoplastic Agents chemistry, Docosahexaenoic Acids chemistry, Eicosapentaenoic Acid chemistry, Fishes, Liposomes chemistry
- Abstract
Breast cancer is the leading cause of death from cancer among women. Higher consumption of dietary marine n-3 long-chain polyunsaturated fatty acids (LC-PUFAs) is associated with a lower risk of breast cancer. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are two n-3 LC-PUFAs found in fish and exert anticancer effects. In this study, natural marine-derived lecithin that is rich in various polyunsaturated fatty acids (PUFAs) was extracted from salmon heads and transformed into nanoliposomes. These nanoliposomes were characterized and cultured with two breast cancer lines (MCF-7 and MDA-MB-231). The nanoliposomes decreased the proliferation and the stiffness of both cancer cell types. These results suggest that marine-derived lecithin possesses anticancer properties, which may have an impact on developing new liposomal delivery strategies for breast cancer treatment., Competing Interests: The authors declare no conflict of interest.
- Published
- 2020
- Full Text
- View/download PDF
27. Beta-Cell-Specific Expression of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 5 Aggravates High-Fat Diet-Induced Impairment of Islet Insulin Secretion in Mice.
- Author
-
Bouzakri K, Veyrat-Durebex C, Holterman C, Arous C, Barbieux C, Bosco D, Altirriba J, Alibashe M, Tournier BB, Gunton JE, Mouche S, Bietiger W, Forterre A, Berney T, Pinget M, Christofori G, Kennedy C, and Szanto I
- Subjects
- Animals, Cells, Cultured, Diet, High-Fat adverse effects, Female, Humans, Insulin Secretion drug effects, Male, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, NADPH Oxidase 5 metabolism, Islets of Langerhans metabolism, NADPH Oxidase 5 genetics
- Abstract
Aims: Nicotinamide adenine dinucleotide phosphate oxidases (NOX-es) produce reactive oxygen species and modulate β-cell insulin secretion. Islets of type 2 diabetic subjects present elevated expression of NOX5. Here, we sought to characterize regulation of NOX5 expression in human islets in vitro and to uncover the relevance of NOX5 in islet function in vivo using a novel mouse model expressing NOX5 in doxycycline-inducible, β-cell-specific manner (RIP/rtTA/NOX5 mice). Results: In situ hybridization and immunohistochemistry employed on pancreatic sections demonstrated NOX5 messenger ribonucleic acid (mRNA) and protein expressions in human islets. In cultures of dispersed islets, NOX5 protein was observed in somatostatin-positive (δ) cells in basal (2.8 m M glucose) conditions. Small interfering ribonucleic acid (siRNA)-mediated knockdown of NOX5 in human islets cultured in basal glucose concentrations resulted in diminished glucose-induced insulin secretion (GIIS) in vitro . However, when islets were preincubated in high (16.7 m M ) glucose media for 12 h, NOX5 appeared also in insulin-positive (β) cells. In vivo , mice with β-cell NOX5 expression developed aggravated impairment of GIIS compared with control mice when challenged with 14 weeks of high-fat diet. Similarly, in vitro palmitate preincubation resulted in more severe reduction of insulin release in islets of RIP/rtTA/NOX5 mice compared with their control littermates. Decreased insulin secretion was most distinct in response to theophylline stimulation, suggesting impaired cyclic adenosine monophosphate (cAMP)-mediated signaling due to increased phosphodiesterase activation. Innovation and Conclusions: Our data provide the first insight into the complex regulation and function of NOX5 in islets implying an important role for NOX5 in δ-cell-mediated intraislet crosstalk in physiological circumstances but also identifying it as an aggravating factor in β-cell failure in diabetic conditions.
- Published
- 2020
- Full Text
- View/download PDF
28. Efficacy of Dupilumab for Controlling Severe Atopic Dermatitis in a Patient with Hyper-IgE Syndrome.
- Author
-
Lévy R, Béziat V, Barbieux C, Puel A, Bourrat E, Casanova JL, and Hovnanian A
- Subjects
- Acute Disease, Female, Humans, Middle Aged, Receptors, Interleukin-4 immunology, Treatment Outcome, Anti-Allergic Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Dermatitis, Atopic drug therapy, Job Syndrome diagnosis
- Published
- 2020
- Full Text
- View/download PDF
29. The Role of Inflammation in β-cell Dedifferentiation.
- Author
-
Nordmann TM, Dror E, Schulze F, Traub S, Berishvili E, Barbieux C, Böni-Schnetzler M, and Donath MY
- Subjects
- Animals, Anti-Inflammatory Agents pharmacology, Cells, Cultured, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental etiology, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 etiology, Humans, Inflammation physiopathology, Insulin-Secreting Cells drug effects, Insulin-Secreting Cells metabolism, Male, Mice, Mice, Inbred C57BL, Cell Dedifferentiation, Cytokines metabolism, Diabetes Mellitus, Experimental pathology, Diabetes Mellitus, Type 2 pathology, Inflammation complications, Insulin metabolism, Insulin-Secreting Cells pathology
- Abstract
Chronic inflammation impairs insulin secretion and sensitivity. β-cell dedifferentiation has recently been proposed as a mechanism underlying β-cell failure in T2D. Yet the effect of inflammation on β-cell identity in T2D has not been studied. Therefore, we investigated whether pro-inflammatory cytokines induce β-cell dedifferentiation and whether anti-inflammatory treatments improve insulin secretion via β-cell redifferentiation. We observed that IL-1β, IL-6 and TNFα promote β-cell dedifferentiation in cultured human and mouse islets, with IL-1β being the most potent one of them. In particular, β-cell identity maintaining transcription factor Foxo1 was downregulated upon IL-1β exposure. In vivo, anti-IL-1β, anti-TNFα or NF-kB inhibiting sodium salicylate treatment improved insulin secretion of isolated islets. However, only TNFα antagonism partially prevented the loss of β-cell identity gene expression. Finally, the combination of IL-1β and TNFα antagonism improved insulin secretion of ex vivo isolated islets in a synergistic manner. Thus, while inflammation triggered β-cell dedifferentiation and dysfunction in vitro, this mechanism seems to be only partly responsible for the observed in vivo improvements in insulin secretion.
- Published
- 2017
- Full Text
- View/download PDF
30. Artemisinins Target GABA A Receptor Signaling and Impair α Cell Identity.
- Author
-
Li J, Casteels T, Frogne T, Ingvorsen C, Honoré C, Courtney M, Huber KVM, Schmitner N, Kimmel RA, Romanov RA, Sturtzel C, Lardeau CH, Klughammer J, Farlik M, Sdelci S, Vieira A, Avolio F, Briand F, Baburin I, Májek P, Pauler FM, Penz T, Stukalov A, Gridling M, Parapatics K, Barbieux C, Berishvili E, Spittler A, Colinge J, Bennett KL, Hering S, Sulpice T, Bock C, Distel M, Harkany T, Meyer D, Superti-Furga G, Collombat P, Hecksher-Sørensen J, and Kubicek S
- Subjects
- Animals, Artemether, Artemisinins administration & dosage, Carrier Proteins metabolism, Cell Transdifferentiation drug effects, Cells, Cultured, Diabetes Mellitus drug therapy, Diabetes Mellitus, Type 1 pathology, Gene Expression Profiling, Homeodomain Proteins metabolism, Humans, Insulin genetics, Insulin metabolism, Islets of Langerhans drug effects, Membrane Proteins metabolism, Mice, Protein Stability drug effects, Rats, Single-Cell Analysis, Transcription Factors metabolism, Zebrafish, gamma-Aminobutyric Acid metabolism, Artemisinins pharmacology, Diabetes Mellitus, Type 1 drug therapy, Disease Models, Animal, Receptors, GABA-A metabolism, Signal Transduction
- Abstract
Type 1 diabetes is characterized by the destruction of pancreatic β cells, and generating new insulin-producing cells from other cell types is a major aim of regenerative medicine. One promising approach is transdifferentiation of developmentally related pancreatic cell types, including glucagon-producing α cells. In a genetic model, loss of the master regulatory transcription factor Arx is sufficient to induce the conversion of α cells to functional β-like cells. Here, we identify artemisinins as small molecules that functionally repress Arx by causing its translocation to the cytoplasm. We show that the protein gephyrin is the mammalian target of these antimalarial drugs and that the mechanism of action of these molecules depends on the enhancement of GABA
A receptor signaling. Our results in zebrafish, rodents, and primary human pancreatic islets identify gephyrin as a druggable target for the regeneration of pancreatic β cell mass from α cells., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
31. Asymmetrical distribution of δ and PP cells in human pancreatic islets.
- Author
-
Barbieux C, Parnaud G, Lavallard V, Brioudes E, Meyer J, Alibashe Ahmed M, Berishvili E, Berney T, and Bosco D
- Subjects
- Adolescent, Adult, Aged, Fluorescent Antibody Technique, Humans, Middle Aged, Pancreatic Polypeptide metabolism, Somatostatin metabolism, Tissue Distribution, Young Adult, Islets of Langerhans cytology, Islets of Langerhans metabolism, Pancreatic Polypeptide-Secreting Cells cytology, Pancreatic Polypeptide-Secreting Cells metabolism, Somatostatin-Secreting Cells cytology, Somatostatin-Secreting Cells metabolism
- Abstract
The aim of this study was to evaluate the location of PP and δ cells in relation to the vascularization within human pancreatic islets. To this end, pancreas sections were analysed by immunofluorescence using antibodies against endocrine islet and endothelial cells. Staining in different islet areas corresponding to islet cells adjacent or not to peripheral or central vascular channels was quantified by computerized morphometry. As results, α, PP and δ cells were preferentially found adjacent to vessels. In contrast to α cells, which were evenly distributed between islet periphery and intraislet vascular channels, PP and δ cells had asymmetric and opposite distributions: PP staining was higher and somatostatin staining was lower in the islet periphery than in the area around intraislet vascular channels. Additionally, frequencies of PP and δ cells were negatively correlated in the islets. No difference was observed between islets from the head and the tail of the pancreas, and from type 2 diabetic and non-diabetic donors. In conclusion, the distribution of δ cells differs from that of PP cells in human islets, suggesting that vessels at the periphery and at the centre of islets drain different hormonal cocktails., (© 2016 Society for Endocrinology.)
- Published
- 2016
- Full Text
- View/download PDF
32. DDB2 (damaged-DNA binding 2) protein: a new modulator of nanomechanical properties and cell adhesion of breast cancer cells.
- Author
-
Barbieux C, Bacharouche J, Soussen C, Hupont S, Razafitianamaharavo A, Klotz R, Pannequin R, Brie D, Bécuwe P, Francius G, and Grandemange S
- Subjects
- Cell Adhesion, Female, Humans, MCF-7 Cells, Microscopy, Atomic Force, Neoplasm Metastasis, Breast Neoplasms chemistry, Breast Neoplasms metabolism, Breast Neoplasms ultrastructure, DNA-Binding Proteins biosynthesis, Elastic Modulus, Gene Expression Regulation, Neoplastic, Neoplasm Proteins biosynthesis
- Abstract
DDB2, known for its role in DNA repair, was recently shown to reduce mammary tumor invasiveness by inducing the transcription of IκBα, an inhibitor of NF-κB activity. Since cellular adhesion is a key event during the epithelial to mesenchymal transition (EMT) leading to the invasive capacities of breast tumor cells, the aim of this study was to investigate the role of DDB2 in this process. Thus, using low and high DDB2-expressing MDA-MB231 and MCF7 cells, respectively, in which DDB2 expression was modulated experimentally, we showed that DDB2 overexpression was associated with a decrease of adhesion abilities on glass and plastic areas of breast cancer cells. Then, we investigated cell nanomechanical properties by atomic force microscopy (AFM). Our results revealed significant changes in the Young's Modulus value and the adhesion force in MDA-MB231 and MCF7 cells, whether DDB2 was expressed or not. The cell stiffness decrease observed in MDA-MB231 and MCF7 expressing DDB2 was correlated with a loss of the cortical actin-cytoskeleton staining. To understand how DDB2 regulates these processes, an adhesion-related gene PCR-Array was performed. Several adhesion-related genes were differentially expressed according to DDB2 expression, indicating that important changes are occurring at the molecular level. Thus, this work demonstrates that AFM technology is an important tool to follow cellular changes during tumorigenesis. Moreover, our data revealed that DDB2 is involved in early events occurring during metastatic progression of breast cancer cells and will contribute to define this protein as a new marker of metastatic progression in this type of cancer.
- Published
- 2016
- Full Text
- View/download PDF
33. Cell rearrangement in transplanted human islets.
- Author
-
Lavallard V, Armanet M, Parnaud G, Meyer J, Barbieux C, Montanari E, Meier R, Morel P, Berney T, and Bosco D
- Subjects
- Animals, Extracellular Matrix metabolism, Glucagon-Secreting Cells metabolism, Heterografts, Humans, Insulin-Secreting Cells metabolism, Male, Mice, Mice, SCID, Extracellular Matrix pathology, Glucagon-Secreting Cells pathology, Insulin-Secreting Cells pathology, Islets of Langerhans Transplantation
- Abstract
The major feature of the human pancreatic islet architecture is the organization of endocrine cells into clusters comprising central β cells and peripheral α cells surrounded by vasculature. To have an insight into the mechanisms that govern this unique islet architecture, islet cells were isolated, and reaggregation of α and β cells into islet-like structures (pseudoislets) after culture or transplantation into mice was studied by immunohistology. The pseudoislets formed in culture displayed an unusual cell arrangement, contrasting with the transplanted pseudoislets, which exhibited a cell arrangement similar to that observed in native pancreatic islet subunits. The pattern of revascularization and the distribution of extracellular matrix around transplanted pseudoislets were alike to those observed in native pancreatic islets. This organization of transplanted pseudoislets occurred also when revascularization was abolished by treating mice with an anti-VEGF antibody, but not when contact with extracellular matrix was prevented by encapsulation of pseudoislets within alginate hydrogel. These results indicate that the maintenance of islet cell arrangement is dependent on in vivo features such as extracellular matrix but independent of vascularization., (© FASEB.)
- Published
- 2016
- Full Text
- View/download PDF
34. Single-cell transcriptomes reveal characteristic features of human pancreatic islet cell types.
- Author
-
Li J, Klughammer J, Farlik M, Penz T, Spittler A, Barbieux C, Berishvili E, Bock C, and Kubicek S
- Subjects
- Adult, Cells, Cultured, Gene Expression Profiling methods, Gene Expression Profiling standards, Genetic Markers, Humans, Insulin-Secreting Cells classification, Male, Single-Cell Analysis methods, Single-Cell Analysis standards, Insulin-Secreting Cells metabolism, Transcriptome
- Abstract
Pancreatic islets of Langerhans contain several specialized endocrine cell types, which are commonly identified by the expression of single marker genes. However, the established marker genes cannot capture the complete spectrum of cellular heterogeneity in human pancreatic islets, and existing bulk transcriptome datasets provide averages across several cell populations. To dissect the cellular composition of the human pancreatic islet and to establish transcriptomes for all major cell types, we performed single-cell RNA sequencing on 70 cells sorted from human primary tissue. We used this dataset to validate previously described marker genes at the single-cell level and to identify specifically expressed transcription factors for all islet cell subtypes. All data are available for browsing and download, thus establishing a useful resource of single-cell expression profiles for endocrine cells in human pancreatic islets., (© 2015 The Authors. Published under the terms of the CC BY NC ND 4.0 license.)
- Published
- 2016
- Full Text
- View/download PDF
35. Interaction of Iron II Complexes with B-DNA. Insights from Molecular Modeling, Spectroscopy, and Cellular Biology.
- Author
-
Gattuso H, Duchanois T, Besancenot V, Barbieux C, Assfeld X, Becuwe P, Gros PC, Grandemange S, and Monari A
- Abstract
We report the characterization of the interaction between B-DNA and three terpyridin iron II complexes. Relatively long time-scale molecular dynamics (MD) is used in order to characterize the stable interaction modes. By means of molecular modeling and UV-vis spectroscopy, we prove that they may lead to stable interactions with the DNA duplex. Furthermore, the presence of larger π-conjugated moieties also leads to the appearance of intercalation binding mode. Non-covalent stabilizing interactions between the iron complexes and the DNA are also characterized and evidenced by the analysis of the gradient of the electronic density. Finally, the structural deformations induced on the DNA in the different binding modes are also evidenced. The synthesis and chemical characterization of the three complexes is reported, as well as their absorption spectra in presence of DNA duplexes to prove the interaction with DNA. Finally, their effects on human cell cultures have also been evidenced to further enlighten their biological effects.
- Published
- 2015
- Full Text
- View/download PDF
36. Manganese superoxide dismutase in breast cancer: from molecular mechanisms of gene regulation to biological and clinical significance.
- Author
-
Becuwe P, Ennen M, Klotz R, Barbieux C, and Grandemange S
- Subjects
- Animals, Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Proliferation, Enzyme Induction, Female, Gene Expression Regulation, Neoplastic, Humans, Neoplasm Invasiveness, Oxidative Stress, Polymorphism, Genetic, Superoxides metabolism, Breast Neoplasms enzymology, Superoxide Dismutase physiology
- Abstract
Breast cancer is one of the most common malignancies of all cancers in women worldwide. Many difficulties reside in the prediction of tumor metastatic progression because of the lack of sufficiently reliable predictive biological markers, and this is a permanent preoccupation for clinicians. Manganese superoxide dismutase (MnSOD) may represent a rational candidate as a predictive biomarker of breast tumor metastatic progression, because its gene expression is profoundly altered between early and advanced breast cancer, in contrast to expression in the normal mammary gland. In this review, we report the characterization of some gene polymorphisms and molecular mechanisms of SOD2 gene regulation, which allows a better understanding of how MnSOD is decreased in early breast cancer and increased in advanced breast cancer. Several studies display the biological significance of MnSOD level in proliferation as well as in invasive and angiogenic abilities of breast tumor cells by controlling superoxide anion radical (O2(•-)) and hydrogen peroxide (H2O2). Particularly, they report how these reactive oxygen species may activate some signaling pathways involved in breast tumor growth. Emerging understanding of these findings provides an interesting framework for guiding translational research and suggests a way to define precisely the clinical interest of MnSOD as a prognostic and/or predicting marker in breast cancer, by associating with some regulators involved in SOD2 gene regulation and other well-known biomarkers, in addition to the typical clinical parameters., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
37. DDB2: a novel regulator of NF-κB and breast tumor invasion.
- Author
-
Ennen M, Klotz R, Touche N, Pinel S, Barbieux C, Besancenot V, Brunner E, Thiebaut D, Jung AC, Ledrappier S, Domenjoud L, Abecassis J, Plénat F, Grandemange S, and Becuwe P
- Subjects
- Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Breast Neoplasms genetics, Cell Line, Tumor, Cell Movement genetics, Female, Humans, I-kappa B Proteins genetics, I-kappa B Proteins metabolism, MCF-7 Cells, Matrix Metalloproteinase 9 genetics, Matrix Metalloproteinase 9 metabolism, NF-KappaB Inhibitor alpha, NF-kappa B metabolism, Neoplasm Invasiveness, Prognosis, Promoter Regions, Genetic, Transcription, Genetic, Up-Regulation genetics, Breast Neoplasms metabolism, Breast Neoplasms pathology, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, NF-kappa B genetics
- Abstract
The DNA repair protein damaged DNA-binding 2 (DDB2) has been implicated in promoting cell-cycle progression by regulating gene expression. DDB2 is selectively overexpressed in breast tumor cells that are noninvasive, but not in those that are invasive. We found that its overexpression in invasive human breast tumor cells limited their motility and invasiveness in vitro and blocked their ability to colonize lungs in vivo, defining a new function for DDB2 in malignant progression. DDB2 overexpression attenuated the activity of NF-κB and the expression of its target matrix metalloprotease 9 (MMP9). Mechanistic investigations indicated that DDB2 decreased NF-κB activity by upregulating expression of IκBα by binding the proximal promoter of this gene. This effect was causally linked to invasive capacity. Indeed, knockdown of DDB2-induced IκBα gene expression restored NF-κB activity and MMP9 expression, along with the invasive properties of breast tumor cells overexpressing DDB2. Taken together, our findings enlighten understanding of how breast cancer cells progress to an invasive phenotype and underscore potential clinical interest in DDB2 as a prognostic marker or therapeutic target in this setting.
- Published
- 2013
- Full Text
- View/download PDF
38. [Cystic pneumatosis of the colon and professional trichloroethylene exposure].
- Author
-
Lefrou L, Barbieux JP, Barbieux C, and Metman EH
- Subjects
- Adult, Biopsy, Colonoscopy, Follow-Up Studies, Humans, Male, Oxygen Inhalation Therapy, Solvents poisoning, Trichloroethylene poisoning, Occupational Diseases chemically induced, Pneumatosis Cystoides Intestinalis chemically induced, Solvents adverse effects, Trichloroethylene adverse effects
- Published
- 2007
- Full Text
- View/download PDF
39. [Acute cerebellar syndrome after treatment with 5-fluorouracil].
- Author
-
Barbieux C, Patri B, Cerf I, and de Parades V
- Subjects
- Alcoholism complications, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cisplatin adverse effects, Diagnosis, Differential, Drug Tolerance, Female, Fluorouracil therapeutic use, Humans, Middle Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Squamous Cell drug therapy, Cerebellar Ataxia chemically induced, Fluorouracil adverse effects, Tonsillar Neoplasms drug therapy
- Abstract
We report on a case of 5-fluorouracil induced neurotoxicity during 5-fluorouracil cisplatin combination chemotherapy for advanced head and neck squamous cell carcinoma. The initial manifestations included an acute cerebellar syndrome and peripheral neuropathy. Computed tomography of the brain was normal. The results of nerve-conduction studies were compatible with the diagnosis of distal sensory neuropathy. The patient experienced improvement, without treatment, four weeks after cessation of chemotherapy. The role of cisplatin and alcohol abuse in this neurotoxic episode, can not yet completely be excluded.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.